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We all have a dream: all of us want to live a long, healthy, and suc c essful life in full possession of our physic al and mental fac ulties, surrounded by family and friends. We all want to be respec ted, to feel that we are needed, and to be useful and happy at work and in family life. Lives c ut off before their time, people we c are for often, and inc reasingly leaving us for eternity while young or middle-aged, sometimes at the peak of their c apac ities, leaving painful and c ontinuously open wounds in families, soc iety, and the ec onomy. All of us bear a responsibility for c hanging this situation.
The most often public ized North-Karelia Program was set into motion in Finland in 1 9 7 2 in response to a loc al petition. The program ac hieved its suc c ess rate through c ooperation on all levels of government, and offered urgent and effec tive assistanc e in reduc ing an extremely high level of mortality from c oronary heart disease. While this program ran, it reduc ed the mortality rate from c oronary heart disease among the male population by about 5 0 %. The program foc used on organizing ongoing c are for people with hypertension, and on a public information c ampaign that inc reased the ratio of the people overall for whom physic al fitness bec ame a element in their lifestyle, while reduc ing the number of c igarette smokers at the same time. A national dietary and nutritional polic y also was put into operation. It inc luded a full-sc ale public educ ation program c ombined with promoting the manufac ture of an inc reased variety of healthy foods and introduc ing healthy diets to public meal servic es. In other words, there is an existing model that c an be adapted to most Central-European c onditions and, if it is implemented c onsistently, suc c ess is guaranteed.
However, good programs alone are not enough. Suc c ess also requires the kind of c ooperation by all of soc iety that we have been able to muster several times before in our history, and whic h has seen us through some hard times. We are c urrently in the midst of one of these historic al watersheds. We only will be able to c lose down our transition to a new politic al system and bec ome a suc c essful and integral part of Europe if we c an prevent the loss of our supreme resourc e, the c reative power of our c itizens, and if our population stops dec lining. This requires determination and innovative program designs by government and proac tive partic ipation by all of soc iety in the belief that it c an be done. To see results in ten to twenty years, we need to go into motion immediately, in our own private lives as well as on a soc iety-wide sc ale. The only real guarantee of a suc c essful future for Hungary is our people, people who are aware of what needs to be done and are ready to ac t for their own sake and for the sake of their c hildren!
T he H ungarian situation
The overall state of public health in Hungary has been in c ontinuous dec line for more than thirty years. In 1 9 9 9 , average life expec tanc y at birth for the male population was 6 6 .3 7 years, and for the females it was 7 5 .2 4 years, well below the European Union average ( where in 1 9 9 7 the rate for males was 7 4 .8 4 years and for females it was 8 1 .2 4 years) , and also lower than c orresponding data from neighboring Central and Eastern European nations. The mortality rate for middle-aged males is partic ularly high, even in worldwide c omparisons. Although there has been a slight improvement here in rec ent years, the c onsensus of opinion is that a substantive breakthrough in this very slowly improving trend will require soc iety-wide and c oordinated intervention.
The leading c auses of mortality in people under the age of 6 5 ( whic h qualifies as premature) are disorders of the c irc ulatory system ( the same as for overall mortality) . Within these disorders, high blood pressure plays a dec isive role in the onset of c oronary heart disease ( primarily myoc ardial infarc tion) and c erebrovasc ular diseases ( stroke and other c erebrovasc ular ac c idents) . Among Hungarians, premature mortality due to c oronary heart disease is three times the average rate for the European Union, and it is four times that average for c erebrovasc ular diseases. Mortality due to malignant neoplasms is also far in exc ess of the EU average ( 1 .8 -times higher) . Among men, lung c anc er is the type of tumour c ausing the highest death rate, while among females the prime killers are breast and c ervic al c anc er. Hungary's premature male mortality rate from lung c anc er and premature female mortality rate from c ervic al c anc er are partic ularly high when c ompared to the EU average. The male premature lung c anc er mortality rate is 2 .5 times over the EU average, and the female premature c ervic al c anc er mortality rate is 3 .5 times higher. At the same time, premature mortality due to malignant c olon and c olorec tal tumours has been rising in both men and women. Another ac ute problem is the 7 -8 -fold inc rease in premature mortality due to c hronic liver diseases and c irrhosis of the liver -mostly alc ohol-induc ed -over the past 3 0 years. By the mid-1 9 9 0 s this mortality rate was sevenfold ( 7 -fold!) the EU average. Death due to violenc e needs to be c ut in half to meet the EU average. Within the c auses of violent death, premature mortality due to suic ide c ontinues to be more than double the average level among EU-residents, even though it has dec lined c ontinuously over the past dec ade.
Underlying c auses inc lude unhealthy lifestyles, shortc omings in health habits, environmental pollution, the c ountry's ec onomic development level, diffic ulties with performanc e, soc ial inequality, and a substandard level of healthc are. Many people smoke c igarettes and are heavy smokers to boot, c onsume unhealthy foods, are c ompletely sedentary, c onsume exc essive amounts of alc ohol, pursue self-destruc tive lifestyles, pay no attention to their health, avoid sc reening programmes, and do not utilize other forms of healthc are either. The fac tor that a b o vo c auses differenc es in lifestyle is soc ial inequality -the sc ale of differenc es between the poorest and ric hest strataprinc ipally the result of differenc es in the educ ation level, and the ensuing employment and inc ome c onditions. Health problems appear c umulatively among disadvantaged soc ial groups, the groups that were the losers when the politic al system c hanged. Traditional relationships have lost their adhesive power, and c entury-long generational bonds have c ollapsed. Rural residents are even less healthy than urban ones.
T he N ew H ungarian Program: Goals, T asks, and Projects
Contemporary health promotion/public health programs are based on the following princ iples:
• Individual health is determined predominantly by environment and lifestyle.
• Determinants of health relate to one another in a c omplex manner and the predominant fac tors are generally not pathology-spec ific -in other words, they c an trigger any of a number of diseases.
• An individual's immediate environment ( family, workplac e, leisure time, etc .) is able to influenc e personal lifestyles ( whic h have a dec isive influenc e on health) , bec ause of the individual's natural need to be part of a c ommunity and to meet c ommunity expec tations.
• Improving public health requires ac tion by all of soc iety, inc luding inter-sec toral c ooperation and ac c eptanc e of responsibility, and a partnership between all players that make up soc iety ( c entral government, loc al government, and grass roots c ommunities) .
T he Five N ational T argets to reach by 2010
Health has to bec ome a supreme human value for the vast majority of the public , whic h in turn has to be made ready to ac t to maintain its health. Dec ision-makers, both in legislation and in setting the budget, have to give a top priority to improving the nation's health.
1 Conditions for healthy development have to be guaranteed for upc oming generations, from c onc eption to adulthood.
2 Years of life spent in good health have to be extended for both males and females.
3 Average life expec tanc y at birth has to be extended to at least 7 0 years for men and 7 8 years for women.
4 Soc ial inequalities and differenc es in life expec tanc y at birth have to be reduc ed. 
T en Priority N ational T asks

Seventeen Programs to reach the targets and implement the tasks
The 1 7 implementation programs inc lude ones that are targeted spec ific ally at c ombating disorders that play the greatest role in quality-of-life deterioration and mortality ( c ardiovasc ular diseases, tumours, mental disorders, and mobility impairments) . There are also non-spec ific ac tion plans and key measures that target health determinants ( educ ation, nutrition, exerc ise, tobac c o smoking, drug use and alc ohol c onsumption) . By implementing them, health c an be improved and the risks of multiple diseases and disorders c an be reduc ed.
1 Reduc ing mortality due to myoc ardial infarc tion 
Reducing Mortality Due to Myocardial Infarction:
The Target:
To reduce mortality due to coronary heart disease among the under-6 5 population by 2 0 % by 2 0 1 0 .
The Situation:
Diseases of the c irc ulatory system are the leading c ause of death in Hungary. Coronary heart diseases, in partic ular myoc ardial infarc tion are the list leaders. Circ ulatory system disorders are responsible for one out of every three deaths among the under-6 5 population. Self-destruc tive lifestyles -typic ally c igarette smoking; unhealthy nutrition and a lac k of exerc ise; neglec ted, insuffic iently, or poorly treated hypertension; and often the shortc omings of ac ute c are, whether oc c urring separately or in c ombination, put all of us at inc reased risk or further reduc e our c hanc es for a fuller, healthy and c reative life.
While, in Western Europe, c hanges in nutritional habits, an inc reased interest in exerc ise, and up-to-date drug therapies have reduc ed mortality due to c irc ulatory system disorders ( c oronary heart disease, c erebrovasc ular ac c idents, peripheral vasc ular disorders, and aorta anomalies) by 4 0 -5 0 % sinc e 1 9 7 0 , mortality rates in Hungary have inc reased. As a result of these two opposing trends, in 1 9 9 7 premature deaths ( oc c urring at ages 0 -6 4 ) from c irc ulatory disorders inc luding c oronary heart disease were three times over the average for the European Union, and even exc eeded c orresponding average mortality rates for the populac es of the Central and East European nations.
All three of the key fac tors -lifestyle, environment and healthc are -probably c ontributed to the trends evolving over past dec ades. As far as the healthc are servic e is c onc erned, shortc omings in preventive, c urative, and rehabilitation servic es for c ardiovasc ular patients were probably major c ontributors to the deterioration in c ardiovasc ular health, though there also have been enc ouraging results in rec ent years. From 1 9 9 7 there has been a small but steady dec line in c oronary heart disease among men aged 1 5 to 6 4 , inc luding a drop in mortality from ac ute myoc ardial infarc tion. Today, the rate of properly treated hypertensive patients ranges from 1 7 % to 2 8 %, depending on geographic region and the partic ular population being surveyed. This rate c an be pushed up to 9 0 % with the proper c ontinuing educ ation of physic ians and with patient educ ation.
Other nations report a great deal of suc c ess in preventing c oronary heart disease. Finland instituted a program c alled The North-Karelia Program in 1 9 7 2 , in response to a loc al plea. The program, whic h offered urgent and effec tive help in reduc ing an extremely high mortality rate from c oronary heart disease, ac hieved its suc c ess rate bec ause of c ooperation by all levels of government. Results show that in 1 9 7 2 some 5 2 % of the male population smoked c igarettes, a figure that dec lined to 3 2 % by 1 9 9 2 . Dietary c hanges suc c eeded in reduc ing the total c holesterol level by 1 5 % among the population of North-Karelia. The program also involved c ontinuous c are for hypertensive patients, and an information c ampaign that inc reased the portion of the public that exerc ised regularly. During the time the program ran, the c oronary heart disease mortality rate among the male population of North-Karelia dropped by about 5 0 %. Between 1 9 7 0 and 1 9 9 6 , mortality from c oronary heart disease dropped by about 6 5 % among under-6 5 males and females. ( In 1 9 7 0 the death rate of Finnish males from c oronary heart disease was 2 .4 times higher than it was for Hungarian males, while today it is just slightly more than half that rate, i.e., 5 8 %)
A working group of leading professionals c ame together over two years ago, and were given the task of designing the best national program it c ould, tangibly to reduc e Hungary's mortality rate from myoc ardial infarc tion within a 1 0 year time frame.
Goals up to 2010:
• Reduc ing mortality due to c oronary heart disease among the under-6 5 population by 2 0 %.
• Inc reasing the effec tiveness of regular sc reening for hypertension.
• Inc reasing the rate of hypertensive patients under regular treatment to at least 8 5 %.
• Introduc ing effec tive treatment of hypertension to inc rease the rate of patients whose blood pressure is lower than the threshold value of 1 4 0 /9 0 Hgmm to at least 5 0 %.
• Advanc ing methods for the primary and sec ondary prevention of c ardiovasc ular diseases: promoting healthy nutrition, promoting physic al exerc ise, reduc ing c igarette smoking, inc reasing the foc us on health improvement within the educ ational system.
Indicators:
• Myocardial in farction m ortality data. Risk fac tors: data on c igarette smoking, diet, nutrition, exerc ise ( see c orresponding sub-programs) .
• Coron ary heart disease m orbidity data ( incide nce , pre va le nce ) . Rate of hypertensive patients rec eiving regular treatment, rate of patients with satisfactory blood pressure readings.
1 Surveying the prevalenc e of high blood pressure and of risk fac tors, c onduc ting population surveys and c ollec ting morbidity data.
2 Sc reening the population for high blood pressure ( see separate sec tion) .
3 Improving the quality in primary health c are for hypertension.
4 Running a satisfac tory pharmac eutic al c are program for hypertensive patients on an ongoing basis.
5 Designing, establishing, and operating a national registry of hypertensive patients and the setting up the information system needed for it.
6 Elaborating the organizational and operational c onditions for hypertension treatment fac ilities, and ac c rediting their operation.
7 Introduc ing extension c ontinuing educ ation and training programs both for patients, for the public at large, as well as for physic ians and allied health personnel.
8 Improving the c onditions for emergenc y c are.
9 Healthy nutrition: reduc ing c holesterol levels and obesity.
1 0 Promoting physic al exerc ise.
1 1 Reduc ing smoking.
1 2 Health promotion in the educ ational system.
Reducing Mortality due to cerebrovascular diseases T he T arget:
To reduce permanent damage and mortality from cerebrovascular diseases, and to decrease CVD incidence.
The Situation:
Stroke is the third leading c ause of death in Hungary following c oronary artery oc c lusions and tumours, just as in the developed nations of the world. International trends and a World Health Organization projec tion strongly suggest that as populations of industrial soc ieties grow older, there will be a shift in the leading c auses of mortality, and stroke will bec ome even more signific ant as a leading c ause of death.
In the 1 9 5 0 s, death due to stroke was more or less equal to the average for Europe. But from then on, until 1 9 8 0 , the stroke mortality rate in Hungary inc reased enormously, signific antly exc eeding the European average, and was the sixth highest in Europe. Despite a steady dec line sinc e the early 1 9 8 0 s, the stroke mortality rate is still more than double the European Union average, for both males and females. In 1 9 9 9 , over 1 9 ,0 0 0 Hungarians died of strokes.
The stroke mortality rate is partic ularly high among the under-6 5 s, nearly 4 .5 times over the EU average for males and 3 .5 times higher for females.
Hemorrhages or blood c lots resulting in permanent damage ( non-transient isc hemic attac ks) lead to death within 3 0 days in 1 2 -2 0 % of c ases and to death within one year in 2 5 -3 0 %. The overall stroke survival rate for all types of stroke is no more than 2 -3 years following the onset of the ac c ident. About 6 0 -7 0 % of people suffering stroke are not taken to spec ialized hospital wards. The result is a roughly 4 % higher mortality rate during the ac ute phase of the attac k than oc c urs in fac ilities spec ialized in strokes, whic h translates into over 5 0 0 avoidable deaths eac h year.
Another c onsequenc e of c erebrovasc ular diseases is permanent damage to health in 6 0 % of c ases overall, manifest not only in physic al symptoms ( paralysis, diffic ulties in understanding or voc alizing speec h, loss of the ability to swallow) , but also in injury to thought proc esses in 2 0 % of c ases, and in depression in 4 0 %. Quality of life deteriorates signific antly.
Brain damage is one of the most signific ant fac tors behind the deterioration in quality of life among the elderly. A stroke qualifies as a disaster, not only for the patient but also for the family and for soc iety in general. The c ondition requires long-term c are, whic h makes it one of the most expensive, and physic ally and emotionally exhausting of all c onditions.
The problem of c are for stroke patients first bec ame a c entre of foc us in 1 9 8 8 , and in 1 9 9 2 it was widely public ized with the announc ement of a National Stroke Program. However, figures on inc idenc e in 2 0 0 1 show the c ontinued urgent need to elaborate and introduc e an updated strategy enabling the nation to signific antly reduc e the overall inc idenc e of stroke, the mortality due to stroke, and the other burdens inc urred.
Goals up to 2010:
• Reduc ing ac ute stroke mortality by 3 0 %.
• Reduc ing morbidity by 3 0 %.
• Treating a larger ratio of stroke patients in spec ialized wards or fac ilities.
• Broadly promoting the following in working towards the primary and sec ondary prevention of vasc ular disorders: promoting healthy nutrition, promoting physic al exerc ise, reduc ing smoking and alc ohol c onsumption, inc reasing the foc us on health promotion within the educ ational system.
• Improving the effec tiveness of sc reening for hypertension, and treating hypertensive patients.
• Creating a framework for effec tive rehabilitation.
• Designing the c riteria for c entrally ac c rediting stroke wards by 2 0 0 2 , and enforc ing them subsequently. Re-establishing a national database suitable for epidemiologic al studies Indicators:
• Stroke mortality data.
• Stroke morbidity data ( inc idenc e, prevalenc e) .
• Risk fac tors: data on smoking, diet, nutrition, physic al exerc ise ( see c orresponding sub-programs) .
• Frequenc y of referral to spec ialized fac ility.
• Frequenc y of permanent damage to health.
• Frequenc y of post-stroke depression, suic ide.
Actions:
1 1 Reduc ing exc essive alc ohol c onsumption. 
Primary prevention
Primary prevention generally means the effort to modify risk fac tors or prevent their development with the aim of delaying or preventing new-onset CHD.
Concept of Risk Factors
The c onc ept of risk fac tors c onstitutes a major advanc e for developing strategies for preventing CHD. The major r isk factor s are cigar ette smoking, hyper tension, high ser um cholester ol and var ious cholester ol fr actions, low levels of high-density lipopr otein ( HDL) cholester ol, and diabetes mellitus. Advancing age is also inc luded as a risk fac tor bec ause of inc reased absolute risk with aging.
Fac tors other than those listed as major risk fac tors inc rease the likelihood for developing CHD. Among these, whic h have been studied at Framingham or elsewhere, are obesity, physic al inac tivity, family history of premature CHD, hypertriglyc eridemia, small low-density lipoprotein ( LDL) partic les, inc reased lipoprotein ( a) ( Lp[ a] ) , inc reased serum homoc ysteine, and abnormalities in several c oagulation fac tors.
Despite the potential importanc e of these other fac tors, they are not inc luded in the risk c harts for both theoretic al and prac tic al reasons. Nonetheless, they deserve some c omment and c onsideration of reasons for omission.
Framingham researc h reveals that both obesity and physical inactivity are positively assoc iated with risk for CHD. Even so, Framingham data suggest that obesity and physic al inac tivity exert muc h of their adverse influenc e on development of CHD through the major risk fac tors.
Certainly it is possible that some of the inc reased risk imparted by obesity and physic al inac tivity results from mec hanisms unrelated to the major risk fac tors. However, these mec hanisms are not well understood, and it is diffic ult to define the risk imparted by these 2 fac tors independent of their influenc e on the major risk fac tors. Certainly both public health and c linic al efforts to promote desirable body weight and regular exerc ise deserve a high priority in prevention.
Family histor y undoubtedly gives useful information
about an individual's risk status. However, the independent effec t of a positive family history is diffic ult to determine. Almost c ertainly familial influenc es on risk status are mediated in part through blood pressure and serum lipoprotein levels. Even so, a positive family history of premature CHD c annot be ignored in c linic al evaluation. Not only should suc h a history inc rease awareness that an individual is at greater risk, but it c alls for evaluation of other family members who may c arry heritable risk fac tors.
Framingham risk sc ores do not inc lude ser um tr iglyceride levels. Muc h researc h c onfirms that elevated serum triglyc erides are signific antly c orrelated with risk. However, a c ontroversy has raged for many years over whether elevated triglyc erides are an independent risk fac tor. For example, triglyc eride levels are inversely c orrelated with serum HDL-c holesterol levels. This approac h does not nec essarily mean that triglyc eride-ric h lipoproteins are not atherogenic . There is growing evidenc e that c ertain spec ies of these lipoproteins are in fac t atherogenic and probably should be targets of therapy. Even so, for risk assessment, HDL-c holesterol levels reflec t a signific ant portion of the risk imparted by higher serum-triglyc eride c onc entrations.
Another lipoprotein abnormality, small dense LDL partic les, is likewise strongly assoc iated with low serum HDL-c holesterol levels. Small dense LDL partic les may promote atherosc lerosis.
Future researc h will be required to define the independent c ontributions of the 3 c omponents of the atherogenic lipoprotein phenotype -elevated triglyc eride-ric h lipoproteins, small LDL partic les, and reduc ed HDL c holesterol -to overall CHD risk. Use of serum HDLc holesterol levels to define the risk ac c ompanying this c omplex phenotype is undoubtedly an oversimplific ation, but this drawbac k is partially offset by c linic al usefulness.
Lp( a) may be still another lipid risk fac tor. Several reports indic ate that elevated serum Lp( a) c onc entrations are assoc iated with high risk for CHD. Although other reports fail to doc ument a signific ant link between Lp( a) levels and CHD rates, the preponderanc e of the evidenc e seems to support a signific ant relationship. However, before measurements of Lp( a) levels c an be routinely used in risk predic tion, a stronger link between Lp( a) and atherogenesis must be established, and ac c urate and inexpensive measurements must be widely available.
Another c ategory of c andidate risk fac tors inc ludes abnor malities in sever al coagulation factor s.
Among these fac tors are platelet hyperreac tivity, high levels of hemostatic proteins ( fibr inogen and fac tor IV) , defec tive fibr inolysis, and hyper viscosity of the blood.
The most extensive epidemiologic al data link plasma fibrinogen c onc entrations to CHD risk.
In addition, evidenc e suggests that plasma markers for endothelial c ell injury and inflammation may be predictors of ac ute c oronary events. Researc h on these various fac tors promises to provide new insights into the pathogenesis of CHD, but their quantitative roles have not been determined suffic iently to inc lude them in risk predic tion equations. Moreover, ac c urate measurements of these c oagulation fac tors are not yet widely available to prac tic ing physic ians.
In rec ent years there has been a growing interest in the possibility that a c ondition c alled insulin r esistance underlies several metabolic risk fac tors, predisposing the individual to premature CHD. Insulin resistanc e refers to a generalized metabolic disorder in whic h various tissues are resistant to normal levels of plasma insulin. Metabolic abnormalities inc lude defec tive gluc ose uptake by skeletal musc le, inc reased release of free fatty ac ids by adipose tissue, overproduc tion of gluc ose by the liver, and hypersec retion of insulin by panc reatic ß -c ells. The presenc e of insulin resistanc e c an usually be detec ted c linic ally by trunc al ( or abdominal) obesity and hyperinsulinemia. CHD risk fac tors often present in patients with insulin resistanc e inc lude the atherogenic lipoprotein phenotype, hypertension, impaired gluc ose toleranc e, and a prothrombotic state. This c lustering of several metabolic risk fac tors in a single patient has been termed the metabolic syndrome.
The final risk predic tor is serum homoc ysteine level. Persons with the rare c ongenital disorder homoc ysteinuria develop severe arterial disease; this disc overy gave rise to the theory that high homoc ysteine levels may be a c ause of CHD. Furthermore, ac c ording to several studies, moderately elevated serum levels of homoc ysteine in the general population are positively assoc iated with CHD oc c urrenc e. In addition, patients with a genetic defec t in an enzyme produc ing high homoc ysteine levels also appear to be at inc reased risk for CHD. Whether measurement of plasma homoc ysteine c onc entrations is c linic ally useful in risk stratific ation is unc ertain but worthy of further investigation Ac c ording to the most rec ent US panel ( JAMA, 2 0 0 1 ) , the two major modalities of LDL-lowering therapy are therapeutic lifestyle c hanges ( TLC) and drug therapy ( Table 2 ) . The TLC Diet stresses reduc tions in saturated fat and c holesterol intakes. When the metabolic syndrome or its assoc iated lipid risk fac tors ( elevated triglyc eride or low HDL c holesterol) are present, TLC also stresses weight reduc tion and inc reased physic al ac tivity. The table below defines LDL c holesterol goals and c utpoints for initiation of TLC and for drug c onsideration for persons with three c ategories of risk: CHD and CHD risk equivalents; multiple ( 2 + ) risk fac tors ( 1 0 -year risk 1 0 -2 0 % and < 1 0 %) ; and 0 -1 risk fac tor.
• Reduc ed intakes of saturated fats ( < 7 % of total c alories) and c holesterol ( < 2 0 0 mg per day)
• Therapeutic options for enhanc ing LDL lowering suc h as plant stanols/sterols ( 2 g/day) and inc reased visc ous ( soluble) fiber ( 1 0 -2 5 g/day)
• Weight reduc tion • Inc reased physic al ac tivity
Secondary prevention
The term sec ondary prevention denotes therapy to reduc e rec urrent CHD events and dec rease c oronary mortality in patients with established CHD. Sec ondary prevention strategy is aimed at both c ontrol of risk fac tors and direc t therapeutic protec tion of c oronary arteries from plaque eruption. This dual approac h has led some investigators to view sec ondary prevention efforts as treatment of c oronary artery disease. Although there may be a slim distinc tion between sec ondary prevention and high-risk primary prevention, onc e a patient has exhibited c linic al atherosc lerotic disease, he or she is unequivoc ally at very high risk for developing new ac ute c oronary events. For purposes of sec ondary prevention, manifest atherosc lerotic disease inc ludes angina pec toris or history of doc umented myoc ardial infarc tion, history of c oronary artery proc edures ( bypass graft, angioplasty) , peripheral arterial disease, aortic aneurysm, symptomatic c oronary artery disease.
Rec ent c linic al trials demonstrate that LDL-lowering therapy reduc es total mortality, c oronary mortality, major c oronary events, c oronary artery proc edures, and stroke in persons with established CHD. An LDL c holesterol level of < 2 .6 mmol/l is optimal; therefore, ATP III spec ifies an Measure patient's weight and height, BMI, and waist-to-hip ratio at each visit as part of routine evaluation.
Start weight management and physical activity as appropriate. Desirable BMI range: 21-25 kg/m 2 ). Desirable waist circumference <101 cm in men and <91 cm in women.
Diabetes management: Near normal fasting
Appropriate hypoglycemic therapy to achieve near normal fasting plasma glucose as indicated by HbA1c. Treatment of other risks (e.g., physical activity, weight management, blood pressure and for cholesterol management see recommendations for patients with coronary disease. TG indic ates triglyc erides; LTs, liver func tion tests; TFTs, thyroid func tion tests; UA, uric ac id; CHD, c oronary heart disease; and BMI, body mass index. LDL c holesterol < 2 .6 mmol/l as the goal of therapy in sec ondary prevention. This goal is supported by c linic al trials with both c linic al and angiographic endpoints and by prospec tive epidemiologic al studies. The same goal should apply for persons with CHD risk equivalents. When persons are hospitalized for ac ute c oronary syndromes or c oronary proc edures, lipid measures should be taken on admission or within 2 4 hours. These values c an guide the physic ian on initiation of LDL-lowering therapy before or at disc harge. Adjustment of therapy may be needed after 1 2 weeks.
For persons with CHD and CHD risk equivalents, the goal is to attain an LDL c holesterol level < 2 .6 mmol/l. Most CHD patients will need LDL-lowering drug therapy. Other lipid risk fac tors may also warrant c onsideration of drug treatment. Whether or not lipid-modifying drugs are used, non-lipid risk fac tors require attention and favorable modific ation. In persons admitted to the hospital for a major c oronary event, LDL c holesterol should be measured on admission or within 2 4 hours. This value c an be used for treatment dec isions.
In general, persons hospitalized for a c oronary event or proc edure should be disc harged on drug therapy if the LDL c holesterol is > 3 .3 mmol/l. If the LDL is 2 .6 -3 .3 mmol/l, c linic al judgment should be used in dec iding whether to initiate drug treatment at disc harge, rec ognizing that LDL c holesterol levels begin to dec line in the first few hours after an event and are signific antly dec reased by 2 4 -4 8 hours and may remain low for many weeks. Thus, the initial LDL c holesterol level obtained in the hospital may be substantially lower than is usual for the patient.
Some authorities hold drug therapy should be initiated whenever a patient hospitalized for a CHD-related illness is found to have an LDL c holesterol > 2 .6 mmol/l. Initiation of drug therapy at the time of hospital disc harge has two advantages. First, at that time patients are partic ularly motivated to undertake and adhere to risk-lowering interventions; and sec ond, failure to initiate indic ated therapy early is one of the c auses of a large "treatment gap," bec ause outpatient follow-up is often less c onsistent and more fragmented. * Some authorities rec ommend use of LDL-lowering drugs in this c ategory if an LDL c holesterol < 2 .6 mmol/l c annot be ac hieved by therapeutic lifestyle c hanges. Others prefer use of drugs that primarily modify triglyc erides and HDL, e.g., nic otinic ac id or fibrate. Clinic al judgment also may c all for deferring drug therapy in this subc ategory.
